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Abstract: Crataeva tapia bark lectin was evaluated for its antitumor activity against sarcoma 180 in Swiss albino mice. The anti-
inflammatory and analgesic properties were investigated in models of inflammation and nociception. The anti-inflammatory assay 
was induced by carrageenan induced peritonitis and the analgesic activity was induced by acetic acid-induced writhing response. 
The lectin presents low toxicity with a LD50 of 2,500 mg/kg body weight and significant antitumor activity causing inhibition of 
tumor growth. The lectin also promoted significant reduction (35.4%) in the number of neutrophil migration induced by carragee-
nan. Concerning its analgesic property, the lectin inhibits abdominal contractions induced by acetic acid. The current results re-
vealed a lectin with significant antitumoral, anti-inflammatory and antinociceptive activities. Further investigations to unveil the 
exact mechanisms are needed. 
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Introduction 
Plants have been a source of medicines for humans since 
pre-history and it is notable that in the last four decades, there 
has been a resurgence of interest in the study and use of me-
dicinal plants. Natural products derived from plants have been 
characterized and identified as new chemical compounds of 
therapeutic importance. Lectins are proteins that can recognize 
and reversibly bind to carbohydrates or other substances de-
rived from sugars1. Nowadays, it is well known that despite 
their small size, sugars play roles in storage or in relaying in-
formation within or between cells. Due to their carbohydrate-
specific interaction, lectins have been versatile and useful mo-
lecular tools for the study of glycoconjugates on the cell sur-
face. Therefore are excellent candidates to be explored in can-
cer research and as therapeutics agents2–5. 
Inflammation is part of the complex biological response of 
vascular tissues to harmful stimuli, such as pathogens, dam-
aged cells, or cancer. Inflammation is usually associated with 
pain as a secondary process resulting from the release of anal-
gesic mediators6. Non-steroidal anti-inflammatory agents – 
NSAIDS have been prepared and marketed6, however, these 
drugs are known to provoke gastrointestinal irritation7. Thus, 
recognition of inflammatory processes incidence caused by 
cancer robustly correlates with an increasing attention on safe-
ty and effectiveness of novel pharmaceuticals. The aim of the 
present study was to investigate the antitumoral, anti-
inflammatory and antinociceptive properties of bark lectin 
from Crataeva tapia on experimentally induced tumors, in-
flammation and pain. 
 
Material and methods 
Purification of Crataeva Tapia Bark Lectin. Crataeva 
tapia bark was obtained through a sequential purification pro-
tocol according to Nascimento et al.8. Bark powder (10g) was 
mixed with150 mM NaCl (100 ml). An extract was obtained 
by agitation of the mixture overnight at 4ºC. The extract was 
filtered through gauze and underwent centrifugation at 4,000 g 
for 15 min. The supernatant was termed crude extract (CE). 
The reversed micellar system was constituted using the anionic 
surfactant, sodium di(2-ethylhexyl)sulfosuccinate in isooctane. 
Extraction and back-extraction procedures were performed as 
follows: (1) to buffered lectin preparations (3 ml) containing 
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30 mM NaCl, an equal volume (3 ml) of micellar phase (AOT 
in isooctane) was added and both phases were stirred for 5 min 
for protein extraction. The mixture was then centrifuged for 5 
min at 3000 g, for phase separation. (2) After extraction, the 
separated micellar phase (2 ml), containing solubilized protein, 
was added to an equivalent volume of buffered aqueous solu-
tion containing KCl and 5% (v/v) of butanol was added to the 
system. The mixture was stirred for 5 min, centrifuged for 5 
min at 3000 g for phase separation and the lectin recovered to 
the new aqueous phase. 
 
Animals. Male albino Swiss mice (Mus musculus) weighing 
approximately 33 g (±50 days old) were obtained from the 
Bioterium of the Centro de Pesquisa Ageu Magalhães / 
FIOCRUZ and maintained under constant conditions (tem-
perature: 23 ± 2°C, humidity: 40–60%, 12 h light/12 h dark 
cycle). The mice were allowed to access standard rodent diet 
(Purina®) and water ad libitum. All experiments involving 
male albino Swiss mice were approved by the Ethics Commit-
tee for Animal Experimentation of the Biological Sciences 
Center of the Federal University of Pernambuco, Brazil 
(CEEA – UFPE-Ofício n° 40/06). 
 
Brine Shrimp Lethality Activity. The assay was modified 
from Meyer et al.9. Artemia salina eggs (25 mg) were hatched 
in natural seawater at temperatures of 20 to 30°C. The pH was 
adjusted between 8.0 and 9.0 using Na2CO3 to avoid risk of 
death to the larvae by decrease of pH during incubation10. A. 
salina bioassay used 5,000 ppm CrataBL (Crataeva tapia Bark 
Lectin) stock solution prepared in seawater: stock solution was 
diluted (110–50 ppm) in vials containing 5 ml of seawater and 
15 A. salina. The control group was placed in diluted stock 
solution.  Both groups were maintained in the solutions for 24 
h. The survival rate was determined and used to estimate LC50. 
The assays were carried out in triplicate. The collected data 
were computerized and the LC50 value estimated using the 
statistical method of probity11. 
 
Acute Oral Toxicity. CrataBL was evaluated following the 
steps of Guideline 42312, using male mice. The mice were 
prevented from eating overnight prior to the experiment. Three 
animals for each preparation were orally given a single dose 
starting at 300 mg/kg (mg of product/kg of body weight) and 
observed for 14 days (during the first hour after treatment and 
then once per day). CrataBL were dissolved in a 0.9% sterile 
NaCl solution and the calculation of the exact dose for each 
mice was based on individual weights. This first step was re-
peated in the same way for confirmation of results and a high-
er dose (2000 mg/kg) was administrated, both using different 
male mice. 
 
Antitumor Activity. The in vivo antitumor activity of 
CrataBL against Sarcoma-180 was carried out in male mice 
(six animals per cage). CrataBL and MTX (methotrexate) 
dosages were calculated according to animal body mass index 
(20 mg/kg for CrataBL and 2.5 mg/kg for MTX). Malign 
tumor cells (Sarcoma-180) from tumor carrier animals were 
used after 8 days of the implantation. Donor mice were 
anaesthetized for tumor suctioning and the ascetic form of the 
tumor was introduced under the right axilla of the receptor 
animals. The treatment, by via the peritoneum, was begun 24 h 
after implantation and continued for 7 days. The negative 
control group received only the vehicle (saline solution) and 
the standard control (positive) received MTX as referential 
antitumor drug. On the eighth day, the animals were sacrificed 
by cervical dislocation and solid tumors excised and weighed. 
Tumor inhibition was expressed as the mean of tumor weight 
for the treated animal group (T) in comparison to the untreated 
control group (C). The tumor inhibition was then calculated 
according to: percentage tumor inhibition = ((C-T)/C)×100. 
Animal experiments were performed according to the NCI 
protocol13. 
 
Anti-inflammatory Assay – Carrageenan-Induced 
Peritonitis. Saline (0.15 M NaCl) solution (control), dexame-
thasone (2 mg/kg), piroxican (10 mg/kg) and indomethacin (10 
mg/kg), as standard drugs, and CrataBL (30mg/kg), as the test 
drug, were administered via the peritoneum to the correspond-
ent groups (6 animals per group). After 1 h, 0.25 ml carragee-
nan (1% in saline solution) injected intraperitoneally was used 
as a phlogistic agent. After 4 h the animals were sacrificed by 
cervical dislocation and immediately submitted to surgery for 
abdominal opening14. The peritoneal cavity was washed with 2 
ml of saline solution with EDTA. Exudates were collected and 
the polymorphonuclear leukocyte (PMNL) count was deter-
mined in a Neubauer chamber after sample dilution in Turk 
solution (1:200). 
 
Analgesic Activity – Acetic Acid-Induced Writhing Re-
sponse. The response to an intraperitoneal injection of acetic 
acid solution, which manifests as a contraction of the ab-
dominal muscles and stretching of the hind limbs, was evalu-
ated using a method adapted from15. Animals (6 per group) 
were pretreated i.p. with CrataBL (30 mg/kg), vehicle (saline 
solution) or piroxican (10 mg/kg) and dipyrone (150 mg/kg) as 
standard drugs. After 1 h, a dose of 0.1 ml/10 g body weight of 
1% acetic acid was injected i.p.. After 10 min, the number of 
writhings during the following 20-min period was counted. 
Inhibition percentage was calculated through the decrease of 
total writhing number in the treated groups against the control 
group. 
 
Statistical Analysis. The results were expressed as mean 
±S.E.M. (n=6) and statistically assessed using one-way 
ANOVA (Origin® 6.0). Significance was defined as p values < 
0.05. 
 
Results and Discussion 
Compound CrataBL promoted A. salina mortality with a 
LC50 of 71.73 µg/ml. According to Meyer et al.9 crude extracts 
and pure substances with LC50 value < 1000 µg/ml are toxic. 
The low value of LC50 determined by A. salina bioassay indi-
cates compounds with potential antineoplastic properties since 
there is good correlation between artemicide activity and cyto-
toxic activity16. At the doses of 300 mg/kg and 2,000 mg/kg, 
mice did not present weight loss or death. LD50 cut-off of 
CrataBL was determined as 2,500 mg/kg body weight, result-
ing in both concentrations used being considered as safe (Cat-
egory 5)14. 
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Treatment of albino Swiss mice with CrataBL (20 mg/kg) 
significantly (p < 0.05) reduced the Sarcoma 180 volume as 
compared to the tumor volume of the control group (Figure 1). 
Antitumor activity of lectin has already been described. 
Cratylia mollis lectin promoted 41% tumor inhibition3. 
We have evaluated the putative anti-inflammatory activity 
of CrataBL using carrageenan-induced paw edema as an in 
vivo model of inflammation and evaluating the exudate from 
CrataBL treated and control groups. Our data showed that the 
lectin promoted significant reduction (35.4%) in the number of 
PMNL in the inflammatory exudate when compared with the 
control group (Figure 2). The paw edema model has been fre-
quently used to assess the anti-edematous effect of natural 
products since carrageenan induces multi-mediated edema 
formation is characterized by intense neutrophil infiltrate and 
the release of inflammatory mediators such as polypeptide 
kinins, prostaglandins, and nitric oxide17,18. Anti-inflammatory 
lectins have already been revealed using the same experi-
mental model used here. The lectin from marine alga Hypnea 
cervicornis significantly decreased neutrophil migration when 
injected into the peritoneal cavity of mice5. Santi-Gadelha et al. 
4 demonstrated that the anti-inflammatory effect of Araucaria 
angustifolia seed lectin involved its carbohydrate binding sites. 
Piroxican and indomethacin are non-steroidal anti-
inflammatory drugs commonly used to reduce fever, pain, 
stiffness, and swelling. It works by inhibiting the production of 
prostaglandins, molecules known to cause these symptoms. 
Dexamethasone is a potent synthetic member of the glucocor-
ticoid class of steroid drugs. It acts as an anti-inflammatory 
and immunosuppressant. It is possible that CrataBL anti-
inflammatory activity may be due to interference with the re-
lease of a cascade of inflammatory mediators since inhibition 
of leukocyte recruitment might prevent inappropriate inflam-
mation19. 
The results of acetic acid-induced writhing responses in 
mice treated with CrataBL and commercial antinociceptive 
drugs are showed in Table 1. It was found that CrataBL and 
drugs at the doses assayed caused a significant inhibition in the 
writhing responses when compared with the control. Re-
searchers have aimed to elucidate different pharmacological 
effects of lectins related to their antinociceptive activity. Study 
with Amansia multifida lectin has demonstrated potent antino-
ciceptive effects of both central and peripheral origin and it 
has been suggested that the analgesic effect possibly involved 
the participation of the opioid system20. Bitencourt et al.5 
demonstrated that the antinociceptive activity of lectin from 
marine alga Hypnea cervicornis may be related to inhibition of 
the release of mediators in response to acetic acid and that the 
activity involved the lectin carbohydrate-binding site. 
It is clear that there is a strong association between the in-
flammatory process and the development of pain6. Experi-
mental studies have demonstrated that the inhibition of neutro-
phil migration reduces hyper-nociception induced by different 
inflammatory stimuli21. Lonchocarpus sericeus lectin de-
creased leukocyte migration and mechanical hyper-
nociception by inhibiting cytokine and chemokine production 
22. CrataBL antinociceptive activity may be associated to its 
anti-inflammatory activity demonstrated here. 
In summary, our work describes interesting biological prop-
erties of lectin from Crataeva tapia bark that not only displays 
a significant antitumor effect but also shows anti-inflammatory 
and antinociceptive activities. Further investigations to unveil 
the exact mechanisms are needed. 
Figure 1.  Effect of CrataBL and MTX [methotrexate] on 
growth of Sarcoma-180 in male albino Swiss mice. Each 
column represents the mean of six animals and vertical lines 
show the S.E.M. Asterisks denote the significance level in 
comparison to control value: *P  0.05. 
Figure 2.  Effect of pre-treatment with dexamethasone, piroxi-
can, indomethacin [standard drugs] and CrataBL on migration 
of polymorphonuclear leukocytes [PMNL] [number of 
PMNL/ml exudate] in carrageenan-induced peritonitis in mice. 
Each column represents the mean of six animals and vertical 
lines show the S.E.M. Asterisks denote the significance level in 
comparison to control value: *P  0.05. 
Table 1. Antinociceptive activity of CrataBL and analgesic 
drugs. 
compound dose mean  S.E.M. protection (%)
control  64.4  4.1  
piroxican 10 mg/kg 44.7  1.6 32.7 
dipyrone 150 mg/kg 19.8  1.9 73.6 
CrataBL 30 mg/kg 42.0  4.1 34.8


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